IMpower110更新总生存分析:阿替利珠单抗对比铂类化疗一线治疗PD-L1选定NSCLC
IMpower110是一项开放标签3期试验,随机分配PD-L1表达≥1%的TC或IC的初治转移性NSCLC患者接受阿替利珠单抗或铂类化疗。更新分析显示,在高或中等PD-L1表达WT患者中OS改善无统计学显著性(HR=0.87,95%CI 0.66-1.14,P=0.3091),高PD-L1表达WT患者的探索性分析显示OS获益维持(HR=0.76,95%CI 0.54-1.09)。
要点
- 高或中等PD-L1表达WT患者中阿替利珠单抗对比化疗OS无统计学显著改善。
- 高PD-L1表达WT患者探索性分析显示OS获益维持,中位OS 20.2 vs 14.7个月。
- 安全性数据继续支持阿替利珠单抗,未发现新安全信号。
核心结论
- 在高或中等PD-L1表达WT患者中,阿替利珠单抗对比化疗的OS改善无统计学显著性,因此未对任何PD-L1表达WT患者进行正式OS检验。
- 高PD-L1表达WT患者的探索性分析显示阿替利珠单抗组OS获益维持(HR=0.76,95%CI 0.54-1.09;中位OS 20.2 vs 14.7个月)。
- 更新安全性数据继续支持阿替利珠单抗,未发现新安全信号。
研究设计与样本
- 开放标签3期试验,随机分配PD-L1表达≥1%的TC或IC的初治转移性NSCLC患者接受阿替利珠单抗或铂类化疗。
- 主要终点为OS,按PD-L1表达WT亚组分层序贯检验:首先高PD-L1表达亚组,其次高或中等PD-L1表达亚组(TC或IC≥5%),最后任何PD-L1表达亚组(TC或IC≥1%)。
- 任何PD-L1表达WT人群包括554例患者(排除18例EGFR或ALK阳性患者)。
主要发现
- 高或中等PD-L1表达WT患者(n=328)中,阿替利珠单抗对比化疗的OS改善无统计学显著性(HR=0.87,95%CI 0.66-1.14,P=0.3091;中位OS 19.9 vs 16.1个月)。
- 高PD-L1表达WT患者(n=205)探索性分析显示阿替利珠单抗组OS获益维持(HR=0.76,95%CI 0.54-1.09;中位OS 20.2 vs 14.7个月)。
关键数值与推荐
- 高或中等PD-L1表达WT患者中位OS:阿替利珠单抗19.9个月 vs 化疗16.1个月(HR=0.87,95%CI 0.66-1.14,P=0.3091)。
- 高PD-L1表达WT患者中位OS:阿替利珠单抗20.2个月 vs 化疗14.7个月(HR=0.76,95%CI 0.54-1.09)。
临床怎么用
- 对于初治转移性WT NSCLC且高PD-L1表达的患者,支持使用阿替利珠单抗。
- 高或中等PD-L1表达WT患者中阿替利珠单抗对比化疗的OS获益未达统计学显著性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: IMpower110 previously revealed significant overall survival (OS) benefit with atezolizumab versus chemotherapy in patients with treatment-naive EGFR- and ALK-negative (wild type [WT]) metastatic NSCLC with high programmed death-ligand 1 (PD-L1) expression (≥50% on tumor cells [TCs] or ≥10% on tumor-infiltrating immune cells [ICs], per SP142 immunohistochemistry assay; p = 0.0106). We present primary OS analyses in lower PD-L1 expression groups and an updated, exploratory analysis in the high PD-L1 expression group. METHODS: This open-label, phase 3 trial randomized patients with PD-L1 expression on greater than or equal to 1% of TC or IC to receive atezolizumab or platinum-based chemotherapy. The primary end point was OS, hierarchically tested in PD-L1 expression WT subgroups: first the high PD-L1 expression subgroup, then the high-or-intermediate PD-L1 expression subgroup (≥5% on TC or IC), and then the any PD-L1 expression subgroup (≥1% on TC or IC). RESULTS: The any PD-L1 expression WT population included 554 patients (excluded 18 EGFR- or ALK-positive patients). With 17 months' additional follow-up, OS improvement in the atezolizumab versus chemotherapy arm was not statistically significant in high-or-intermediate PD-L1 expression WT patients (n = 328; hazard ratio = 0.87, 95% confidence interval: 0.66-1.14, p = 0.3091; median = 19.9 versus 16.1 mo), precluding formal OS testing in any PD-L1 expression WT patients. Exploratory analysis in high PD-L1 expression WT patients (n = 205) revealed maintained OS benefit in the atezolizumab arm (hazard ratio = 0.76, 95% confidence interval: 0.54-1.09; median = 20.2 versus 14.7 mo). Updated safety data continued to favor atezolizumab. CONCLUSIONS: Statistical significance for OS was not revealed in the high-or-intermediate expression WT group, and, as a result, OS in the any PD-L1 expression WT group was not formally tested. No new safety signals were found. This updated analysis of IMpower110 supports using atezolizumab in treatment-naive, metastatic WT NSCLC with high PD-L1 expression.
引用
- Jassem J, de Marinis F, Giaccone G, et al. Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1-Selected NSCLC. J Thorac Oncol. 2021. PMID: 34265434. doi:10.1016/j.jtho.2021.06.019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。